Pleural Effusion in Cats — Management Guide

Comprehensive, practical guide to causes, diagnosis, emergency care and long-term management of pleural effusion in cats.

Quick Overview

• What it is: Pleural effusion is an abnormal accumulation of fluid in the pleural space (the space between the lungs and chest wall). It reduces lung expansion and causes breathing difficulty.
• Who’s at risk: Any cat can develop pleural effusion. Common underlying causes include congestive heart failure (secondary to cardiomyopathy), neoplasia, feline infectious peritonitis (FIP), pyothorax (septic pleural infection), and chylothorax. Young cats in multi-cat environments are at higher risk for FIP; certain breeds (Maine Coon, Ragdoll) are predisposed to cardiomyopathy, increasing risk of cardiac-related effusion.
• Prognosis: Prognosis depends on cause. Infectious causes (pyothorax) often have good outcomes with drainage and antibiotics (survival commonly 60–90% with aggressive therapy). Chylothorax and neoplasia can be chronic or guarded; FIP historically carried a poor prognosis but antiviral therapies have produced remission in many treated cats. Cardiac effusions require lifelong management of heart disease.

Pathophysiology (explained simply)

The pleural space normally contains a tiny amount of lubricating fluid. Effusion develops when fluid production exceeds removal. Mechanisms include:

• Increased hydrostatic pressure (e.g., congestive heart failure) forcing fluid into the pleural space.
• Increased vascular permeability (inflammation or infection such as pyothorax or FIP).
• Decreased oncotic pressure (hypoalbuminemia—rare primary cause in cats).
• Lymphatic obstruction or leakage (chylothorax, caused by thoracic duct rupture or obstruction).
• Neoplastic invasion disrupting pleural membranes or lymphatics.

Breed-specific risk factors and prevalence

• Maine Coon, Ragdoll (and other breeds with inherited hypertrophic cardiomyopathy) — increased risk of congestive heart failure leading to pleural effusion.
• Young purebred and shelter cats — higher risk for FIP in multi-cat environments.
• Outdoor, male, fighting cats — higher risk of penetrating thoracic injury and pyothorax.
• No strong breed predisposition for chylothorax or thoracic tumors, though older cats are more likely to have neoplastic causes.

Common signs:

• Rapid, shallow breathing or increased respiratory effort (sternal or open-mouthed breathing is an emergency)
• Lethargy, weakness
• Reduced appetite
• Coughing (less common in cats than dogs)
• Weight loss or signs of systemic illness

• Mild: Slightly increased respiratory rate at rest, normal behavior.
• Moderate: Marked tachypnea, mild exercise intolerance, decreased appetite.
• Severe (emergency): Open-mouth breathing, cyanosis, collapse, severe lethargy—requires immediate veterinary care.

History and physical exam

• History should include onset, duration, indoor/outdoor status, trauma, exposure to other cats, weight loss, and appetite.
• Auscultation may reveal muffled heart/lung sounds ventrally and dull percussion.

• Thoracic point-of-care ultrasound (TFAST) — rapid, noninvasive detection of pleural fluid and guidance for thoracocentesis.
• Thoracocentesis (see below) — both therapeutic and diagnostic in dyspneic cats.
• Pulse oximetry and arterial blood gas if available (oxygenation assessment).

• Chest radiographs (horizontal beam if dyspneic) to evaluate distribution of fluid and look for masses, pulmonary edema, or concurrent pneumothorax.
• Echocardiography — essential if cardiac cause suspected (identify cardiomyopathy, pericardial disease, and estimate heart function).
• Thoracic ultrasound — helps locate pockets, assess heart, guide sampling.
• CT scan — considered when neoplasia or thoracic duct pathology is suspected and other tests inconclusive.

Collect 2–3 mL if possible and divide into tubes:

• EDTA tube for cytology and cell count.
• Sterile (red-top) tube for aerobic and anaerobic culture (especially if pyothorax suspected).
• Plain tube for biochemistry (total protein) and specific tests such as triglycerides.

• Appearance: Clear/straw — transudate/modified transudate; turbid/opaque/milky — chyle or septic; hemorrhagic — blood or malignant.
• Cell count and differential: Neutrophilic with intracellular bacteria = septic pyothorax. Lymphocytic predominance + high triglycerides = chylothorax. Mixed inflammation and high protein → FIP suspicious.
• Protein and specific gravity: High protein exudates suggest inflammation/infection or FIP.
• Pleural fluid:serum triglyceride ratio: fluid triglycerides higher than serum supports chylothorax; lipoprotein electrophoresis is gold standard if available.
• Cytology for neoplastic cells — lymphoma can sometimes be diagnosed on fluid cytology but many carcinomas will require biopsy.
• Rivalta test and FCoV PCR/antibody, plus high acute phase proteins (alpha-1 acid glycoprotein), support FIP diagnosis (see specialist for confirmation).

• Indications: any dyspneic cat with suspected pleural effusion. Thoracocentesis often provides rapid clinical improvement.
• Technique: aseptic clipping of a lateral thoracic site, sedation or gentle restraint, 18–22G over-the-needle catheter or dedicated thoracocentesis needle, attach three-way stopcock and syringe or closed collection system. Ultrasound guidance reduces complications.
• Volume: remove enough fluid to relieve respiratory distress but avoid rapid removal of very large volumes (risk of re-expansion pulmonary edema). Many clinicians remove in stages and reassess. Typical approach: remove until respiratory effort improves or up to an initial 20–40 mL/kg, then re-evaluate.
• Complications: pneumothorax, hemorrhage, re-expansion pulmonary edema (rare but potentially fatal), and introduction of infection.

• Oxygen supplementation — cage oxygen or flow-by oxygen immediately.
• Thoracocentesis — immediate therapeutic drainage for respiratory compromise.
• Analgesia/sedation: use cautiously. Opioids (e.g., buprenorphine 0.01–0.03 mg/kg IV/IM/SC) can relieve stress and pain; full opioid agonists (e.g., hydromorphone) may be used under guidance.
• Diuretics: if congestive heart failure is the cause, furosemide (loop diuretic) is commonly used. Typical acute dosing: furosemide 1–4 mg/kg IV or SC, repeated as needed; some patients benefit from IV bolus then CRI under monitoring. Avoid aggressive IV fluids in suspected cardiac cases.
• Antibiotics: if pyothorax suspected, begin broad-spectrum IV antibiotics after sampling (see below). Be guided by culture results.
• ICU monitoring: pulse oximetry, ECG if arrhythmia suspected, frequent reassessment.

1) Congestive heart failure (cardiogenic effusion)

• Acute: oxygen, thoracocentesis as needed, IV/SC furosemide (1–4 mg/kg), consider vasodilators carefully; treat arrhythmias if present.
• Long-term: treat underlying cardiomyopathy—ACE inhibitors (e.g., benazepril 0.5–1 mg/kg PO q24h), pimobendan (off‑label in cats; discuss with cardiologist), and chronic diuretics (furosemide PO 1–2 mg/kg q12–24h or adjusted to effect). Regular cardiology follow-up and echocardiography.

• Drainage: intermittent or indwelling chest tube drainage with lavage is standard.
• Antibiotics: start empirically after sampling — combinations that cover aerobic and anaerobic bacteria (e.g., ampicillin-sulbactam 30 mg/kg IV q8–12h or cefazolin + metronidazole; enrofloxacin 5 mg/kg PO/IV q24h may be considered for gram-negative coverage but use cautiously and guided by culture). Adjust to culture and sensitivity. Duration commonly 4–6 weeks, depending on response.
• Prognosis: guarded to good with aggressive drainage and appropriate antibiotics (survival reported 60–90% in treated populations).

• Medical: low-fat diet and rutin (a benzopyrone) have been used with variable success. Repeated thoracocenteses or pleural catheters for recurrent effusion.
• Surgical: thoracic duct ligation combined with pericardiectomy and pleurodesis (mechanical or chemical) is commonly recommended when medical management fails — reported success rates vary but many series report 60–80% long-term control when combined procedures are used.
• Interventional: pleuroperitoneal shunt is an option for palliative control in some cases.

• Treatment depends on tumor type and extent. Pleural drainage is often palliative.
• Lymphoma may respond to systemic chemotherapy; epithelial tumors (carcinomas, mesothelioma) often carry a worse prognosis and may require surgery, chemotherapy, or palliative care.

• Historically fatal, but antiviral nucleoside analogs (e.g., GS‑441524) have shown high clinical remission rates in published studies (~70–90% depending on stage and protocol). These drugs are not universally licensed and treatment requires specialist guidance and monitoring.

• Frequency of rechecks depends on cause. Cardiac cases require regular cardiology appointments and titration of diuretics. Pyothorax and chylothorax patients require monitoring for recurrence, electrolyte imbalances, and signs of infection.
• Home monitoring: resting respiratory rate (a useful early indicator of deterioration), appetite, activity, and coughing/respiratory effort.
• Diagnostics at follow-up: repeat chest radiographs/ultrasound to document recurrence and evaluate response; bloodwork to monitor kidney function with chronic diuretics.

• The prognosis ranges widely by cause:

Living With Pleural Effusion — practical daily tips

• Monitor resting respiratory rate and effort: a consistent, elevated resting rate or increased effort signals a need for veterinary review.
• Provide a quiet, stress-free environment and avoid heat/exertion that can worsen dyspnea.
• Follow medication schedules precisely; keep a log of doses and recheck dates.
• Home oxygen is not usually recommended without veterinary instruction, but short-term supplemental oxygen during crises can be arranged by your clinic.
• Maintain good nutrition; appetite stimulants can be discussed if anorexia develops.

Seek immediate veterinary care if your cat shows any of the following:

• Open-mouth breathing or gasping
• Collapse or marked weakness
• Blue/pale gums (cyanosis)
• Sudden severe worsening of breathing

Key drug and dose concepts (examples — individual dosing should be determined by your veterinarian)

• Furosemide (acute): 1–4 mg/kg IV/SC, repeat as needed; maintenance PO dosing commonly 1–2 mg/kg q12–24h, titrated.
• Buprenorphine (analgesia): 0.01–0.03 mg/kg IV/IM/SC (also used transmucosally).
• Ampicillin-sulbactam (empiric antibiotic for pyothorax): ~30 mg/kg IV q8–12h (adjust per renal function and culture results).
• Enrofloxacin (if indicated for gram-negative coverage): 5 mg/kg PO/IV q24h (use with caution in kittens and at recommended feline doses).

• Thoracocentesis and pleural fluid analysis: cytology, protein, cell count, triglycerides, culture.
• Imaging: thoracic radiographs, point-of-care ultrasound, echocardiography; CT for complex cases.

• ACVIM (American College of Veterinary Internal Medicine): https://www.acvim.org
• Merck Veterinary Manual — Pleural Effusion: https://www.merckvetmanual.com
• Pedersen NC, et al. Efficacy of GS‑441524 in naturally occurring FIP (Journal of Feline Medicine and Surgery / PubMed): https://pubmed.ncbi.nlm.nih.gov/30620587/

Frequently Asked Questions